The drug, mdc-TJK (TEV-44749), is a once-monthly subcutaneous injection and represents an atypical antipsychotic olanzapine formulation. It is being developed as a long-acting option that could potentially be the first of its kind to offer a favorable safety profile. This development comes as a significant step, especially considering the current long-acting injectable (LAI) olanzapine carries an FDA black box warning for Post injection Delirium/Sedation Syndrome (PDSS), which has limited its use.
1 Like
1 Like
Lol